Christopher Downs - 28 Apr 2023 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Role: Chief Financial Officer
Signature: /s/ Christopher Downs
Issuer symbol: CNSP
Transactions as of: 28 Apr 2023
Net transactions value: $0
Form type: 4
Filing time: 01 May 2023, 18:59:47 UTC
Previous filing: 18 Apr 2023
Next filing: 23 Aug 2023
SEC: View on sec.gov

Quoteable Key Fact

"Christopher Downs filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 01 May 2023."

Quick Takeaways

This page summarizes Christopher Downs's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
2 reported transactions and 1 derivative row are listed below.
Filing timestamp: 01 May 2023, 18:59.

What Changed

Previous filing in this sequence was filed on 18 Apr 2023.
Current net transaction value: $0.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CNSP	Common Stock	Options Exercise		+521	+5.6%		9,772	28 Apr 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNSP	Restricted Stock Units	Options Exercise		-521	-1.8%		28,248	28 Apr 2023	Common Stock	521		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.

Content

Restricted stock units convert into common stock on a one-for-one basis.

On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.